Abraham Heifets, Atomwise CEO (Atomwise via website)
October 2, 2023 07:00 AM EDT
R&D
AI

Ex­clu­sive: 'Faster is­n't bet­ter' — Atom­wise moves from part­ner­ships to pipeline with TYK2 drug

Andrew Dunn

Senior Biopharma Correspondent

Atom­wise, one of the first star­tups to start pitch­ing an AI rev­o­lu­tion in drug dis­cov­ery just over a decade ago is now tak­ing a page …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Chica­go’s biotech scene is grow­ing up. What’s fu­el­ing it?

Ma­jor PBM re­forms fea­ture in Con­gress' year-end spend­ing bill

In sur­prise move, FDA's No. 2 Bum­pus to leave agency at end of 2024

Pfiz­er’s mes­sage to in­vestors: The ship is steady­ing in 2025 (even if Wash­ing­ton is tur­bu­lent)

Jazz Phar­ma­ceu­ti­cals CEO and co-founder Bruce Cozadd is re­tir­ing

UCB, No­var­tis say a Phase 2a Parkin­son's study failed

A service from the Financial Times